| Literature DB >> 35773432 |
Lele Zhu1, Xiaofei Zhou2,3, Meidi Gu2, Jiseong Kim2,4, Yanchuan Li2,5, Chun-Jung Ko2,6, Xiaoping Xie2,7, Tianxiao Gao2,8, Xuhong Cheng2,9, Shao-Cong Sun10.
Abstract
CD8+ T cells are central mediators of immune responses against infections and cancer. Here we identified Dapl1 as a crucial regulator of CD8+ T cell responses to cancer and infections. Dapl1 deficiency promotes the expansion of tumour-infiltrating effector memory-like CD8+ T cells and prevents their functional exhaustion, coupled with increased antitumour immunity and improved efficacy of adoptive T cell therapy. Dapl1 controls activation of NFATc2, a transcription factor required for the effector function of CD8+ T cells. Although NFATc2 mediates induction of the immune checkpoint receptor Tim3, competent NFATc2 activation prevents functional exhaustion of CD8+ T cells. Interestingly, exhausted CD8+ T cells display attenuated NFATc2 activation due to Tim3-mediated feedback inhibition; Dapl1 deletion rescues NFATc2 activation and thereby prevents dysfunction of exhausted CD8+ T cells in chronic infection and cancer. These findings establish Dapl1 as a crucial regulator of CD8+ T cell immunity and a potential target for cancer immunotherapy.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35773432 DOI: 10.1038/s41556-022-00942-8
Source DB: PubMed Journal: Nat Cell Biol ISSN: 1465-7392 Impact factor: 28.213